Discover the remarkable story of how scientists found a crucial missing piece in cardiac development and why this discovery is revolutionizing our understanding of heart health.
Imagine the intricate dance of early human development, where a tiny embryo must construct the most vital organ—the heart—without a single blueprint. For decades, scientists believed they understood the primary architects of this miraculous process. But in 2013, they discovered they'd been missing a crucial player: ELABELA, a hormone that had been hiding in plain sight.
This tiny molecule, produced even before the embryo has a heart, serves as an essential guide, directing stem cells to form a functioning cardiovascular system. Recent research reveals that ELABELA not only builds hearts but may also heal them, offering new hope for treating conditions from heart failure to preeclampsia. This is the story of how scientists found the missing piece in cardiac development and why this discovery is revolutionizing our understanding of heart health.
To appreciate ELABELA's significance, we must first meet the key players in what scientists call the apelinergic system—the hormonal pathway that regulates cardiovascular development and function.
Discovered in 1993, APJ is a protein that sits on cell surfaces, acting like a cellular satellite dish waiting for signals. It belongs to the G-protein-coupled receptor family, one of the most important families of receptor proteins in our bodies 3 5 . For years after its discovery, APJ was considered an "orphan receptor" because no one knew what natural molecule in the body activated it.
In 1998, scientists finally identified APJ's activating partner—a hormone they named apelin 2 5 . Apelin binds to APJ like a key in a lock, triggering processes that lower blood pressure, improve blood flow, and strengthen heart contractions 3 7 . Researchers believed they had completed the picture—until curious observations emerged.
When scientists created genetically engineered "knockout" mice lacking apelin, they expected severe heart defects. Surprisingly, these mice developed relatively normal hearts 2 5 . But when they created mice lacking the APJ receptor, the results were dramatic: over half of these embryos died with severe heart and blood vessel defects 5 . This paradox suggested a crucial piece was missing—there must be another hormone that activates APJ during early heart development.
In 2013, two independent research teams made the same stunning discovery simultaneously. While studying zebrafish embryos, both groups identified a previously overlooked gene that produced a small protein essential for heart development 2 6 .
One team named it ELABELA (ELA), while the other called it Toddler—reflecting its role in guiding developing cells during embryonic "toddler" stages 3 . The name ELABELA has stuck in most scientific literature.
The discovery was particularly exciting because the gene for ELABELA was hiding in a region of DNA previously classified as "non-coding"—supposedly containing no instructions for making proteins 3 . This revelation reminded scientists how much we still have to learn about our genetic blueprint.
| Form | Description | Key Features |
|---|---|---|
| ELA-54 | The full precursor protein | Contains a signal sequence for secretion |
| ELA-32 | Mature, active form | Primary signaling peptide in cardiovascular system 2 7 |
| ELA-21 | Shorter active form | Retains biological activity 8 |
| ELA-11 | Highly conserved minimal form | Contains the essential receptor-binding region 2 |
What makes ELABELA especially fascinating is its expression pattern: it appears very early in embryonic development, even before the heart begins to form, while apelin shows up much later 2 5 . This timing explains why ELABELA, not apelin, is the crucial director of early cardiovascular development.
While the initial discovery occurred in zebrafish, a crucial 2015 experiment published in Scientific Reports demonstrated that ELABELA's functions extend to mammals, including humans 6 . This research provided the definitive evidence that the ELA-APJ system could be a therapeutic target for human heart conditions.
The experimental results provided compelling evidence for ELABELA's importance:
| Signaling Pathway | ELABELA's Effect | Biological Significance |
|---|---|---|
| cAMP suppression | Dose-dependent inhibition | Regulates heart muscle contraction and energy use |
| ERK1/2 phosphorylation | Rapid activation (within 5 minutes) | Promotes cell survival and blood vessel formation |
| Calcium mobilization | Weak, rapid response (peaked at 40 seconds) | Influences blood vessel constriction/dilation |
Perhaps most dramatically, when the team added ELABELA to the engineered cells with glowing APJ receptors, they witnessed the receptors swiftly moving from the cell surface into the cell within 15-30 minutes 6 . This internalization process is a classic response when a receptor encounters its true ligand—confirming that ELABELA genuinely "unlocks" APJ.
In the functional blood vessel experiments, ELABELA demonstrated a remarkable ability to relax mouse aortic rings by up to 73.7%—comparable to apelin's effect but through a different mechanism 6 . While apelin's vasodilating effect largely depended on the inner lining of blood vessels (endothelium), ELABELA worked effectively even with this layer removed, suggesting it could potentially help damaged blood vessels that no longer respond to other treatments.
Studying this complex hormonal system requires specialized tools and techniques. Here are the key reagents and approaches scientists use to unravel ELABELA's mysteries:
| Research Tool | Function/Description | Application Example |
|---|---|---|
| Recombinant ELA peptides | Lab-produced versions of ELA-32, ELA-21, and ELA-11 | Used to test biological responses in cells and animals 8 |
| APJ receptor antibodies | Proteins that specifically bind to and detect APJ receptors | Allows visualization of where APJ receptors are located in tissues |
| APJ-expressing cell lines | Genetically engineered cells to produce human APJ receptors | Enable standardized testing of receptor activation 6 8 |
| cAMP and ERK assays | Tests that measure changes in key signaling molecules | Quantify how strongly ELA activates different pathways 6 8 |
| Animal disease models | Genetically modified mice or disease-induced models | Study ELA's effects on heart failure, hypertension, etc. |
| Fc-ELA fusion proteins | ELA connected to a stabilizing antibody fragment | Extends ELA's short half-life for therapeutic testing |
This toolkit continues to evolve, particularly as researchers work to overcome ELABELA's natural limitations—especially its very short half-life of only minutes in the bloodstream . Innovative approaches like the Fc-ELA fusion protein, which extends ELABELA's stability to 44 hours, are opening new possibilities for therapeutic development .
While ELABELA's role in embryonic heart development is crucial, its potential applications extend far beyond early development. Research has revealed that this hormone plays protective roles in adult cardiovascular health and various diseases:
ELA's Role: Improves heart function, reduces tissue fibrosis
Potential Therapeutic Application: Fc-ELA-21 fusion protein shows promise in animal models
ELA's Role: Relaxes blood vessels through multiple mechanisms
Potential Therapeutic Application: May offer alternative pathway for blood pressure control
ELA's Role: Reduces cell death from oxygen deprivation
Potential Therapeutic Application: Could limit damage after heart attacks 2
The discovery that ELABELA can activate not only APJ receptors but also VEGFR3 (a key receptor for blood vessel formation) suggests it might work through multiple pathways to promote cardiovascular health . This dual action makes it particularly promising for treating complex conditions like heart failure, where multiple systems malfunction simultaneously.
The journey of ELABELA from an overlooked gene to a potential therapeutic superstar represents a paradigm shift in cardiovascular biology. Research continues to uncover new dimensions of this remarkable hormone:
Several pharmaceutical companies and research institutions are working to develop stable ELABELA-based therapeutics that could be administered for chronic conditions like heart failure or hypertension .
Some researchers are exploring whether measuring ELABELA levels in blood could help diagnose early cardiovascular problems or identify at-risk pregnancies 2 4 .
Intriguingly, different forms of ELABELA and apelin activate different signaling pathways through the same APJ receptor—a phenomenon called "biased agonism" 8 . Scientists are now designing smart drugs that selectively activate only beneficial pathways while avoiding potentially harmful ones.
As research advances, ELABELA continues to exemplify how basic scientific discovery—studying something as seemingly obscure as heart development in zebrafish—can reveal profound insights with far-reaching implications for human health. What was once a hidden hormone guiding our first heartbeat may soon emerge as a powerful ally in our ongoing battle against cardiovascular disease, reminding us that sometimes the most important players are the ones we notice last.
References will be added here manually.